Univariate analysis of correlates of acute intracranial abnormalities on head CT (HCT)
| Univariate analysis | OR (95% CI) | P value |
| Demographics | ||
| Mean age | 1.0 (0.9 to 1.0) | 0.581 |
| Male sex | 0.2 (0.1 to 1.1) | 0.059 |
| Other race compared with Caucasian | 0.6 (0.2 to 2.0) | 0.441 |
| Medication use prior to encounter | ||
| Anticoagulants (direct oral anticoagulants/warfarin) | 2.1 (0.6 to 7.8) | 0.277 |
| Aspirin | 5.8 (1.6 to 21.2) | 0.008 |
| Other antiplatelet agents (ticagrelor, prasugrel, clopidogrel) | 1.4 (0.3 to 6.4) | 0.680 |
| Cirrhosis aetiology compared with alcoholic cirrhosis | ||
| Viral hepatitis B and C | 0.9 (0.3 to 3.3) | 0.888 |
| Combination of alcoholic liver disease and other aetiology | 0.4 (0.1 to 4.0) | 0.463 |
| Metabolic (NASH, haemochromatosis, Wilson’s) | -* | – |
| Autoimmune (AIH, PBC, PSC) | -* | – |
| Cryptogenic/unknown | 0.5 (0.1 to 2.8) | 0.435 |
| Comorbidities | ||
| Atrial fibrillation | 3.4 (1.0 to 11.3) | 0.049 |
| Venous thromboembolic disease | 1.6 (0.2 to 12.9) | 0.655 |
| Coronary artery disease | 3.2 (1.03 to 10.2) | 0.044 |
| Peripheral vascular disease | -* | – |
| MELD score | 1.07 (1.00 to 1.2) | 0.061 |
| Platelet count (cells/mm3) | 1.00 (1.00 to 1.01) | 0.540 |
| Serum haemoglobin (g/L) | 0.93 (0.74 to 1.16) | 0.508 |
| By HCT indication compared with AMS (low-risk indication) | ||
| Presence of high-risk indication | 6.2 (2.0 to 19.3) | 0.002 |
| Focal neurological deficit | 6.2 (1.2 to 33.5) | 0.034 |
| Trauma, fall or syncope | 6.7 (1.9 to 23.9) | 0.003 |
| Headache | -* | – |
| Other indications | 9.0 (0.9 to 84.7) | 0.056 |
*Showed complete separation and hence unable to implement in regression analysis.
AIH, autoimmune hepatitis; AMS, altered mental status.; MELD, model for end-stage liver disease; NASH, non-alcoholic steatohepatitis; PBC, primary biliary cholangitis; PSC, primary sclerosing cholangitis.